Schering Plough and Novartis Sign
Selected Abstract
Schering-Plough and Novartis Sign Agreement Giving Schering-Plough U.S. Marketing Rights to FORADIL(R) AEROLIZER(R) for Respiratory Disease.
Schering-Plough Corporation and Novartis Pharmaceuticals Corporation, an affiliate of Novartis AG , today announced an agreement giving Schering-Plough exclusive U.S. distribution and marketing rights to Novartis' FORADIL(R) AEROLIZER(R) (formoterol fumarate inhalation powder), a selective, ... November 1, 2002; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Schering-Plough and Novartis Sign Agreement Giving Schering-Plough U.S. Marketing Rights to FORADIL(R) AEROLIZER(R) for Respiratory Disease.
|
